INT90674

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2000
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 56
Total Number 56
Disease Relevance 38.01
Pain Relevance 8.58

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

protein modification process (LOX) extracellular space (LOX) oxidoreductase activity (LOX)
extracellular region (LOX) nucleus (LOX)
Anatomy Link Frequency
colon 2
joint 1
platelets 1
LOX (Homo sapiens)
Pain Link Frequency Relevance Heat
licofelone 94 99.98 Very High Very High Very High
Potency 24 99.74 Very High Very High Very High
Inflammation 610 99.00 Very High Very High Very High
cINOD 481 97.80 Very High Very High Very High
Analgesic 3 97.56 Very High Very High Very High
COX2 6 96.90 Very High Very High Very High
COX-2 inhibitor 228 96.72 Very High Very High Very High
cytokine 171 92.08 High High
methotrexate 1 88.04 High High
Osteoarthritis 41 87.68 High High
Disease Link Frequency Relevance Heat
Pancreatic Cancer 20 99.92 Very High Very High Very High
Lung Cancer 399 99.76 Very High Very High Very High
Apoptosis 559 99.68 Very High Very High Very High
Liver Cancer 2 99.64 Very High Very High Very High
Renal Cancer 531 99.56 Very High Very High Very High
Malignant Neoplastic Disease 56 99.28 Very High Very High Very High
Reprotox - General 1 489 99.12 Very High Very High Very High
INFLAMMATION 795 99.00 Very High Very High Very High
Cancer 764 99.00 Very High Very High Very High
Immunotherapy Of Cancer 2 98.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors.
Negative_regulation (inhibitors) of LOX associated with cox2
1) Confidence 0.57 Published 2008 Journal Bioorg. Med. Chem. Section Title Doc Link 18272371 Disease Relevance 0.27 Pain Relevance 0.27
Select inhibitors of COX and LOX are described, including nonsteroidal antiinflammatory drugs (NSAIDs), selective COX-2 inhibitors, curcumin, tea, silymarin and resveratrol, as well as a method useful for evaluating inhibitors of COX.
Negative_regulation (inhibitors) of LOX associated with inflammation, cinod and cox-2 inhibitor
2) Confidence 0.48 Published 2000 Journal Drug Metabol Drug Interact Section Abstract Doc Link 11201293 Disease Relevance 0.80 Pain Relevance 0.15
Therefore, blocking LOX/COX pathways simultaneously may prevent recruitment of
Negative_regulation (blocking) of LOX/COX pathways
3) Confidence 0.42 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.66 Pain Relevance 0.06
compounds has been developed offering a more balanced inhibition of LOX-5 and
Negative_regulation (inhibition) of LOX
4) Confidence 0.42 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.78 Pain Relevance 0.47
compounds showing dual inhibition of LOX-5 and COX-2 such as
Negative_regulation (inhibition) of LOX
5) Confidence 0.42 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.74 Pain Relevance 0.33
However, LOX inhibitors have a more potent effect on cell growth in vitro than COX inhibitors on constitutively
Negative_regulation (inhibitors) of LOX
6) Confidence 0.42 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.58 Pain Relevance 0.23
pathway, may have great potency if involves inhibition of both the LOX and COX pathways and activation
Negative_regulation (inhibition) of LOX associated with potency
7) Confidence 0.42 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.96 Pain Relevance 0.15
So, on the basis of these results, it seemed useful to study the advantages of combination of COX inhibitor with LOX inhibitor and a next step will be the conception of dual inhibitors able to induce the anticarcinogenic and/or to inhibit the procarcinogenic enzymes responsible for polyunsaturated fatty acid metabolism.
Negative_regulation (inhibitor) of LOX
8) Confidence 0.42 Published 2007 Journal Curr Top Med Chem Section Abstract Doc Link 17305571 Disease Relevance 0.47 Pain Relevance 0.12
Another strategy is the development of mixed COX-5 lipoxygenase (LOX) inhibitors--the progenitors of which were benoxaprofen and BW-755C.
Negative_regulation (inhibitors) of LOX
9) Confidence 0.42 Published 2001 Journal J. Physiol. Paris Section Abstract Doc Link 11595413 Disease Relevance 0.43 Pain Relevance 0.60
We have studied the conformational flexibility of three 5-keto-substituted 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofurans (DHDMBFs) which show dual cyclooxygenase (COX) and 5-lipoxygenase (LOX) inhibition and are potential candidates as antiinflammatory agents and analgesics.
Negative_regulation (inhibition) of LOX associated with inflammation and analgesic
10) Confidence 0.41 Published 2000 Journal Indian J. Biochem. Biophys. Section Abstract Doc Link 10983419 Disease Relevance 0.10 Pain Relevance 0.10
In all the investigated cell lines, proliferation inhibition was most effectively achieved under the combined application of butyrate with IM and NDGA, suggesting that inhibition of both cyclooxygenase (COX) and lipoxygenase (LOX) isoenzymes is needed for proliferation inhibition by NSAIDs in tumour cells.
Negative_regulation (inhibition) of LOX associated with cancer and cinod
11) Confidence 0.41 Published 2005 Journal Cancer Detect. Prev. Section Abstract Doc Link 15936596 Disease Relevance 0.31 Pain Relevance 0.27
Nowadays, no data are available concerning the potential use of dual cyclooxygenase (COX)/5-lipoxygenase (LOX) inhibitors as anticancer agents in colon cancer treatment.
Negative_regulation (inhibitors) of LOX in colon associated with immunotherapy of cancer
12) Confidence 0.41 Published 2008 Journal Carcinogenesis Section Abstract Doc Link 18033773 Disease Relevance 0.63 Pain Relevance 0.23
Inhibition of 5-LOX by MK886 results
Negative_regulation (Inhibition) of LOX
13) Confidence 0.37 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.31 Pain Relevance 0.03
INHIBITION OF LOX/COX PATHWAYS
Negative_regulation (INHIBITION) of LOX/COX PATHWAYS
14) Confidence 0.37 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.84 Pain Relevance 0.07
of celecoxib (COX inhibitor), MK886, and REV 5901 (both LOX inhibitors)
Negative_regulation (inhibitors) of LOX
15) Confidence 0.37 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.66 Pain Relevance 0
pathway, a dual inhibition of both LOX and COX pathways has been proposed as a new approach to
Negative_regulation (inhibition) of LOX
16) Confidence 0.31 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.54 Pain Relevance 0.26
combination of LOX and COX specific inhibitors has been described in colon and
Negative_regulation (inhibitors) of LOX in colon
17) Confidence 0.31 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.59 Pain Relevance 0.03
greater sensitivity to this LOX/COX inhibitors combination than malignant cells
Negative_regulation (inhibitors) of LOX associated with malignant neoplastic disease
18) Confidence 0.31 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.66 Pain Relevance 0
revealed that a dual inhibitor against LOX/COX is more effective than a
Negative_regulation (inhibitor) of LOX
19) Confidence 0.31 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.97 Pain Relevance 0.16
dual inhibition of LOX and COX pathways might improve gastric tolerability [45].
Negative_regulation (inhibition) of LOX
20) Confidence 0.31 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.61 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox